Approval for the Proposed Incorporation of a Subsidiary

Date: 04th November, 2026 To, To, Manager - Listing Compliance Head – Listing Operations National Stock Exchange of India Corporate Relationship Limited, Exchange Plaza. C-1, Department, BlockG, BSE Limited Bandra Kurla Complex, Bandra (E), Phiroze Jeejeebhoy Towers, Mumbai - 400 051 Dalal Street, Mumbai 400001 SYMBOL: JSLL SCRIP Code: 544476 Subject: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the SEBI Listing Regulations”)- Approval for the Proposed Incorporation of a Subsidiary. Dear Sir/Madam, Pursuant to Regulation 30, read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform you that the Board of Directors of Jeena Sikho Lifecare Limited (“the Company”), at its meeting held today, i.e. Wednesday, November 04, 2026 at the Registered Office of the Company, has inter alia, considered and approved the proposal to incorporate a Subsidiary in India under the proposed name “Ayugenomics Private Limited”, subject to the requisite statutory approvals and completion of applicable incorporation formalities. The disclosures as required under Regulation 30 of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 and HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated 30th January, 2026 are enclosed herewith as Annexure – A. The said meeting commenced at 03:15 P.M. and concluded at 03:50 P.M. The said information will also be made available on the website of the Company at www.jeenasikho.com Kindly take the above on record. Thanking you, Yours faithfully, For Jeena Sikho Lifecare Limited Manish Grover Managing Director DIN: 07557886 Place: Zirakpur, Punjab Encl: Annexure A ANNEXURE – A The disclosures as required under Regulation 30 of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 and HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated 30th January, 2026. S. No. Items to be disclosed Details 1. Name of the entity, date & country of Name of the proposed entity: incorporation, etc. AYUGENOMICS PRIVATE LIMITED Date of Incorporation: Not applicable as the proposed entity is yet to be incorporated Country of incorporation: India Proposed Authorized Share Capital: Rs. 5,00,000 (Rupees Five Lakh only) comprising 50,000 equity shares of ₹10 each. Turnover: Not Applicable, as the proposed entity is yet to be incorporated. 2. Name of holding company of the Upon incorporation and subscription to its incorporated company and relation with equity share capital, Ayugenomics Private the listed entity Limited will become a subsidiary of Jeena Sikho Lifecare Limited. The Company proposes to hold 60% of the equity share capital of the proposed subsidiary. Post incorporation the proposed subsidiary company will become a related party of Jeena Sikho Lifecare Limited. 3. Industry to which the entity being acquired Ayurveda belongs 4. Brief background about the entity Object of proposed Company are: incorporated in terms of products/line of business To carry on the business of research, development, testing, diagnostics and clinical services that combine genomics and allied omics sciences with Ayurveda and other AYUSH systems of medicine. This includes developing genomics-based panels, tests and software, clinical decision-support and artificial intelligence platforms, and clinical databases and registries. It also includes conducting clinical studies and evidence-generation programmes; developing, validating, manufacturing, licensing and commercialising evidence-based herbal, nutraceutical and botanical products and treatment protocols; and offering wellness, preventive-health, training and certification programmes. The company will work with hospitals, government and state programmes and national and international institutions, including in Japan and other overseas markets. It will seek patents, regulatory approvals and registrations in India and abroad, including CDSCO and the US FDA, and will own and commercialise the intellectual property created by the company. 5. Brief details of any governmental or No governmental or regulatory approvals are regulatory approvals required for the presently required. Any applicable approvals acquisition. shall be obtained as and when required. 6. Nature of consideration - whether cash Cash/Banking Channel. consideration or share swap and details of the same. 7. Cost of acquisition or the price at which the Rs. 3,00,000 i.e 30,000 equity shares at Rs. 10/- shares are acquired. (Rupees Ten Only) each share. 8. Percentage of shareholding/ control 60% equity shares shall be subscribed by the acquired and/ or number of shares Company. acquired. For Jeena Sikho Lifecare Limited Manish Grover Managing Director DIN: 07557886 Place: Zirakpur, Punjab